>340
GMP batches released
>50
Audits completed
>30
Process development projects
>70
Qualified assays and methods
About Oxford Biomedica
We believe in pushing the boundaries of scientific possibility and know it takes exceptional knowledge and innovative processes to make that happen.
- 1st worldwide to administer lentiviral vector gene therapy in vivo
- 1st commercial supplier of lentiviral vectors for a CAR-T therapy
AAV platform
Bring confidence to clinical trials with our proven AAV viral vector development and production process, capable of producing consistently high quality and high titre products.
We have:
- Demonstrated >E15 vg/L titers
- Achieved >90% fully intact vector
- Analytical toolbox with over 45 methods
- Process scales from 2L to 2000L
- Six successful IND/CTA filings
Tech transferred-in
Alongside our own LentiVector® and AAV platform technologies, we have the facilities and expertise to fulfil almost any development need. You define the methods and processes, and we leverage our class-leading capabilities as appropriate.
Latest news
Discover our latest updates.
Preliminary results for the year ended 31 December 2023
Oxford, UK – 29 April 2024: One OXB: Building a pure-play cell and gene therapy CDMO; existing financial guidance affirmed • Chief Executive Officer Dr. Frank Mathias, one year into his role, is successfully leading the transformation of OXB into a global, pure-play, quality and innovation-led cell and gene therapy CDMO • “One OXB” strategy well underway, optimising operations across the UK, US and EU with a streamlined workforce and site-based model • Over 50% growth in both orders and pipeline in 2023: An increase of 54% in contracted value of client orders signed; grew from £85 million in 2022 (excluding COVID-19 vaccine manufacturing) to £131 million in 2023 An increase of 51% in the business development pipeline; from $291 million to $438 million from January to December 2023 • Significant commercial momentum with strong demand for OXB’s CDMO services across all key viral vector types, with an expanded client portfolio including 35 clients and 51 programmes as of April 2024 (April 2023: 18 clients and 34 programmes), now includes new clients gained through Oxford Biomedica (France) • Acquisition of ABL Europe (recently renamed Oxford Biomedica (France)) from Institut Mérieux, completed post-period end, enhances OXB’s bioprocessing and manufacturing footprint in the EU, strengthening the Group’s multi-vector, multi-site model spanning the UK, US and the EU • Reiterates its existing financial guidance communicated to the market • Briefing and webcast for analysts to be held today at 13:00 BST / 08:00 ET – see details below Oxford, UK – 29 April 2024: Oxford Biomedica plc (“Oxford Biomedica” or “the Group”) (LSE: OXB), a quality and innovation-led cell and gene therapy CDMO, today announces its preliminary results for the year ended 31 December 2023. Dr. Frank Mathias, Oxford Biomedica’s Chief Executive Officer, said: “2023 was a year of transformation for Oxford Biomedica. We are building our position as a global pure-play cell and gene therapy CDMO and through our ‘One OXB’ strategy are unifying our operations in the UK, US and the EU, including our newly-acquired sites in France. I am delighted with the positive outcomes of our strategy, which have already resulted in a substantial increase in contracted client orders and our business development pipeline. Despite challenging market conditions, we continue to see strong demand for our CDMO services, further solidifying our position as a world-leading global CDMO in the rapidly expanding cell and gene therapy market. Our focus in 2024 remains on growing our global portfolio of clients and projects across all stages of clinical development whilst completing the integration of our sites. This integration will allow us to better align to the demands of performing as a pure-play CDMO. With a highly experienced Corporate Executive Team and a focus on delivering high-quality CDMO services to our clients, our realigned business is well-positioned to help our clients deliver their transformative treatments to patients and drive long-term sustainable growth for the Group. “I would also like to take this opportunity to express my gratitude to all our employees for their tireless efforts, as well as their perseverance and commitment during a period of significant change for the Group. Their dedication and hard work have been instrumental in our transformation into a pure-play CDMO and achieving the significant milestones along the way.” FINANCIAL HIGHLIGHTS (including post-period events) • Stable core business revenues: Small increase in core business revenues whilst total revenues decreased by 36% to £89.5 million (2022: £140.0 million) due to the non-recurrence of vaccine manufacturing revenues • Rebased business with streamlined cost base Operating EBITDA1 loss of £(52.8) million (2022: £1.6 million) Operating loss of £(184.2) million (2022: £(30.2) million) included £99.3 million impairment charge to the US business driven by the cessation of revenues from Homology Completed c.£30 million reduction in ongoing cost base (on an annualised basis compared to 2023) Due to the decision by Homology to cease clinical activities, the Group performed an impairment assessment of OXB (US) LLC, resulting in an impairment of £99.3 million (2022: £nil). • Balance sheet sufficient to achieve strategic objectives Cash of £103.7 million at 31 December 2023 (2022: £141.3 million); Net cash at 31 December 2023 was £65.2 million (2022: £101.5 million) • Commercial KPIs give confidence in future growth Contracted value of client orders signed in the year ended 31 December 2023 was £131 million, an increase of over 50% compared to £85 million in 2022 Revenue backlog2(including France) at 31 March 2024 stood at £104 million, a growth of 11% from £94 million at 31 December 2023 (excludes order from recently signed commercial agreement); this is the amount of future revenue available to earn from current orders OUTLOOK AND FINANCIAL GUIDANCE • The Group reiterates its existing near term and medium-term financial guidance communicated to the market: 2024 total Group revenues of between £126 million and £134 million, with a three-year revenue CAGR of more than 35% for 2023-2026 Broadly breakeven EBITDA in 2024, excluding the impact of the acquisition of ABL Europe (recently renamed Oxford Biomedica (France)) A modest operating loss in 2024 is expected due to the recently acquired sites in France, which will be fully funded by the €10 million cash funding in ABL Europe (recently renamed Oxford Biomedica (France)) from Institut Mérieux as part of the acquisition The Group expects to achieve Operating EBITDA margins in excess of 20% by the end of 2026, and to be profitable on an EBITDA level in 2025. 1. Operating EBITDA (Earnings Before Interest, Tax, Depreciation, Amortisation, Impairment, revaluation of investments and assets at fair value through profit and loss, and Share Based Payments) is a non-GAAP measure often used as a surrogate for operational cash flow as it excludes from operating profit or loss all non-cash items, including the charge for share based payments. However, deferred bonus share option charges are not added back to operating profits in the determination of Operating EBITDA as they may be paid in cash upon the instruction of the Remuneration Committee. A reconciliation to GAAP measures is provided on page 17. 2. Revenue backlog represents ordered CDMO revenues available to earn. The value of customer orders included in revenue backlog only includes the value of work for which the customer has signed a financial commitment for OXB to undertake, whereby any changes to agreed values will be subject to either change orders or cancellation fees. ANALYST BRIEFING Oxford Biomedica’s management team, led by CEO, Dr. Frank Mathias, CFO, Stuart Paynter, CCO, Dr. Sebastien Ribault and COO, Thierry Cournez, will be hosting a briefing and Q&A session for analysts at 13:00 BST / 8:00 EST today, 29 April, at One Moorgate Place Chartered Accountants Hall, 1 Moorgate Pl, London EC2R 6EA, United Kingdom. A live webcast of the presentation will be available via this link. The presentation will be available on Oxford Biomedica’s website at www.oxb.com If you would like to dial in to the call and ask a question during the live Q&A, please email Oxfordbiomedica@consilium-comms.com ______________ Read the OXFORD BIOMEDICA PLC Preliminary results for the year ended 31 December 2023 in full: Download PDF here Notes Unless otherwise defined, terms used in this announcement shall have the same meaning as those used in the Annual report and accounts. ENQUIRIES Oxford Biomedica plc: Sophia Bolhassan, VP, Corporate Affairs and IR T: +44 (0)1865 783 000 / E: ir@oxb.com ICR Consilium: Mary-Jane Elliott / Angela Gray / Davide Salvi, T: +44 (0)20 3709 5700 RBC Capital Markets (Joint Corporate Brokers): Rupert Walford /Kathryn Deegan, T: +44 (0)20 7653 4000 J.P. Morgan Cazenove (Joint Corporate Brokers): James Mitford / Manita Shinh / Jem de los Santos, T: +44 (0)20 7134 7329 ABOUT OXFORD BIOMEDICA Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenoviral vectors, and other viral vector types. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.
Read moreOxford Biomedica Provides Update on CDMO Services Including New Commercial Agreement
Oxford, UK – 20, March, 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”, “OXB” or “the Company”), a quality and innovation-led cell and gene therapy CDMO, today provides an update on its CDMO services activity. – New and expanded contracts highlight commercial momentum across all viral vector types – OXB now working on multiple late-stage programmes with its portfolio of client programmes progressing to later stage work Year to date, Oxford Biomedica has experienced consistently strong demand for its CDMO services across all key viral vector types, with its portfolio of client programmes transitioning towards later stage work. As a result of commercial developments set out below, OXB is now working on three late-stage programmes. Recently, the Company signed a contract with a new undisclosed US-based biotechnology company for the manufacture of lentiviral vectors as the client prepares for the commercial launch of its CAR-T programme targeting multiple myeloma. Manufacturing will take place in Oxbox, the Company’s Oxford based manufacturing facility. Alongside this, Oxford Biomedica has signed two new programmes with existing clinical-stage clients for projects including Process Development and GMP manufacturing. Furthermore, the Company has signed a new agreement with a US-based client specialising in cardiac gene therapy for the tech transfer, optimisation and manufacture of an adeno-associated virus-based process (AAV). Under the terms of these agreements, Oxford Biomedica will receive payments related to the development and manufacturing of viral vectors for use in clinical trials in addition to certain development and regulatory milestone payments. These payments will support the Company in achieving its medium-term financial guidance announced on 5 March 2024. Dr Sébastien Ribault, Chief Commercial Officer of Oxford Biomedica, commented: “The signing of a late-stage programme, alongside the continued expansion of existing agreements since the start of 2024, demonstrates clients’ confidence in OXB’s ability to deliver process development and GMP manufacturing services. Our Business Development team continues to experience strong demand for process characterisation, validation, and process performance qualification (PPQ) work, showcasing the high quality and reliability of our services. This demand is in line with our forecasts across all key vectors and geographies, validating our growth strategy. We remain confident about our future prospects as the leading global pure-play CDMO in cell and gene therapy and our ability to continue building our client portfolio.” -Ends- Enquiries: Oxford Biomedica plc: Sophia Bolhassan, VP, Corporate Affairs and IR – T: +44 (0) 1865 509 737 / E: ir@oxb.com ICR Consilium: T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com Mary-Jane Elliott / Matthew Neal / Davide Salvi About Oxford Biomedica Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy contract development and manufacturing organisation (CDMO) with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenoviral vectors, and other viral vector types. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.
Read moreBoard changes following transformation to pure-play CDMO business model
Oxford, UK – 11 March 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”, “OXB” or “the Company”), a quality and innovation-led cell and gene therapy CDMO, today announces that CDMO expert, Peter Soelkner, will join the Board as a Non-Executive Director, effective from 15 March 2024. Concurrently, as part of Oxford Biomedica’s transformation into a pure-play CDMO, the Company announces that Catherine Moukheibir and Dr. Michael Hayden have informed the Board that they do not intend to stand for re-election at the upcoming Annual General Meeting in June 2024. Dr. Michael Hayden will continue to be an adviser to the Science and Technology Advisory Committee. Peter Soelkner has more than 30 years’ experience in the global pharmaceutical services industry with significant CDMO expertise. He is currently Managing Director of Vetter Pharma, a global Aseptic Filling and Packaging CDMO, where over the past 15 years he has helped grow revenues from $200 million to more than $1 billion. Prior to Vetter, Mr. Soelkner held various senior positions at Sartorius including Vice President of the Americas region where he expanded the global footprint of the business across the US and multiple sectors. He has an MBA from Columbia Business School, New York and Masters in Chemical Engineering from TU Dortmund University, Germany. Dr. Roch Doliveux, Non-Executive Chairman of Oxford Biomedica, commented: “Alongside OXB’s transformation to become a pure-play viral vector CDMO, the Board of Directors has reviewed its breadth of skills and taken the decision to streamline the Board whilst bolstering its CDMO expertise. In light of this, we are delighted to welcome Peter Soelkner given his impressive track record in significantly growing Vetter, a leading global CDMO from $200m to more than $1bn in revenues. In parallel, Catherine Moukheibir and Dr. Michael Hayden, who have played a defining role in shaping OXB’s new strategy, both volunteered not to stand for re-election at the next AGM given that their strengths lie more in therapeutics rather than CDMO. I would like to personally thank Catherine and Michael for their impeccable service, loyalty and valuable insights.” Peter Soelkner commented: “I am pleased to be joining this innovative, client-centric, global business at such an exciting juncture in the Company’s journey. In my view Oxford Biomedica is extremely well-positioned as a pure-play CDMO and I am excited to apply my skillset and experience to help deliver the strategy to clients, enabling them to deliver life-changing therapies to patients.” Relevant disclosures There are no disclosures required to be made in accordance with LR 9.6.13R. -Ends- Enquiries: Oxford Biomedica plc: Sophia Bolhassan, VP, Corporate Affairs and IR – T: +44 (0) 1865 509 737 / E: ir@oxb.com ICR Consilium: T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com Mary-Jane Elliott / Matthew Neal / Davide Salvi About Oxford Biomedica Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy contract development and manufacturing organisation (CDMO) with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenoviral vectors, and other viral vector types. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.
Read moreDownloads
Learn about our 4th generation lentiviral vector delivery system and how this latest lentiviral vector technology developed at Oxford Biomedica can significantly enhance the development and manufacture of safer and more effective lentiviral vector based.
You can also download brochures for our other unique technologies including our TRiP System™ and LentiStable™ cell lines here.
